Cargando…

Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia

PURPOSE: The present study aimed to compare treatment outcome of idarubicin versus doxorubicin in combination with Ara-C as induction therapy for untreated AML patients. PATIENTS AND METHODS: This retrospective study included 143 patients with de novo AML. All patients received full dose of standard...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sherif, Hemat Afifi, Magdy, Ahmed, Elshesheni, Heba Anees, Ramadan, Sherein Mahmoud, Rashed, Reham A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517376/ https://www.ncbi.nlm.nih.gov/pubmed/34692402 http://dx.doi.org/10.1016/j.lrr.2021.100272

Ejemplares similares

The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Lee, Se Ryeon, et al.
Publicado: (2009)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
por: Rodríguez-Macías, Gabriela, et al.
Publicado: (2023)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients
por: Capria, Saveria, et al.
Publicado: (2012)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials
por: Wang, Hanyu, et al.
Publicado: (2020)

Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
por: Roth, Gaël Stéphane, et al.
Publicado: (2020)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018)

Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea
por: Lee, Dae Hyoung, et al.
Publicado: (2010)

Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia
por: Yoon, Jong Hyung, et al.
Publicado: (2009)

Clinical Significance of MAP-7 and FOXC1 in Egyptian Acute Myeloid Leukemia Patients
por: Nabawy, Safa Mohamed, et al.
Publicado: (2022)

Confocal microscopy of idarubicin localisation.
por: Manfait, M., et al.
Publicado: (1997)

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
por: Saygin, Caner, et al.
Publicado: (2020)

Viral Clearance with Neutrophil Recovery in a Patient with Active COVID-19 Infection and Refractory Acute Myeloid Leukemia Who Underwent Successful Reinduction with Cytarabine/Idarubicin
por: Dean, Erin A., et al.
Publicado: (2022)

Confocal microscopy of idarubicin localisation - reply
por: Duffy, P, et al.
Publicado: (1997)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

A comparative study of idarubicin 12 mg/m(2) and 8 mg/m(2) combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients
por: Zhou, Li, et al.
Publicado: (2016)

Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
por: Chen, Mo, et al.
Publicado: (2022)

FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center
por: Yılmaz Bengoa, Şebnem, et al.
Publicado: (2017)

Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
por: Koh, Kyung-Nam, et al.
Publicado: (2017)

Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma
por: Chehimi, Mohamad, et al.
Publicado: (2016)

Combination of coumarin and doxorubicin induces drug-resistant acute myeloid leukemia cell death
por: Al-Abbas, Nouf S., et al.
Publicado: (2021)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
por: Zeng, Yunxin, et al.
Publicado: (2021)

The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts
por: Dragojew, Sylwia, et al.
Publicado: (2008)

Idarubicin-bromelain combination sensitizes cancer cells to conventional chemotherapy
por: Taşkın, Abdullah, et al.
Publicado: (2019)

Idarubicin–Gold Complex: From Crystal Growth to Gold Nanoparticles
por: Barbey, Carole, et al.
Publicado: (2021)

T-lymphocytes Expression of Toll-like Receptors 2 and 4 in Acute Myeloid Leukemia Patients with Invasive Fungal Infections
por: Abdel Hammed, Muhamad R., et al.
Publicado: (2022)

Fludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemia
por: Sang, Wei, et al.
Publicado: (2016)

Acute myocarditis in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin: a possible relationship with the differentiation syndrome or early anthracycline cardiotoxicity?
por: Nunes, Rafael Amorim Belo, et al.
Publicado: (2023)

High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation
por: Goel, Shakti A., et al.
Publicado: (2014)

Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide
por: Turk, Seyhan, et al.
Publicado: (2020)

Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells
por: Bulut, Ipek, et al.
Publicado: (2022)

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
por: Yao, Han, et al.
Publicado: (2023)

High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients
por: El Nahass, Yasser H, et al.
Publicado: (2022)

Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3
por: Komiyama, Tomoyoshi, et al.
Publicado: (2016)

Insights into idarubicin antimicrobial activity against methicillin-resistant Staphylococcus aureus
por: She, Pengfei, et al.
Publicado: (2020)

Correction to “Idarubicin–Gold Complex: From Crystal Growth to Gold Nanoparticles”
por: Barbey, Carole, et al.
Publicado: (2022)

Transport Mechanisms of Idarubicin, an Anthracycline Derivative, in Human Leukemia HL60 Cells and Mononuclear Cells, and Comparison with Those of Its Analogs
por: Nagasawa, Kazuki, et al.
Publicado: (1997)

Busulfan and Fludarabine Conditioning Regimen Given at Hematological Nadir of Cytoreduction Fludarabine, Cytarabine, and Idarubicin Chemotherapy in Patients With Refractory Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation: A Single Arm Pilot Consort Study
por: Tang, Wei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qshj3amfbg91aqi8e5f02sthdi